Literature DB >> 28804630

Protected cytoskeletal-related proteins: Towards a resolution of contradictions regarding the role of the cytoskeleton in cancer.

Daniel T Segarra1, John M Yavorski1, George Blanck1,2.   

Abstract

Initial reports of the role of the cytoskeleton in cancer indicated that tumor cells with a more disorganized cytoskeleton were more tumorigenic. These reports were based on stains for the F-actin cytoskeleton, for example, using phalloidin or anti-F-actin antibody reagents, and gave a basic impression of F-actin-based cytoskeletal integrity. Later developments emphasized the significance of the cytoskeletal elements in cell migration, presumably associated with either basement membrane invasion or metastasis, or both, with several specific proteins implicated in the formation of cell invadopodia. With the advent of genomics approaches, it has become clear that cytoskeletal related proteins are indeed common targets of mutagenesis in cancer and commonly rank among the most mutated proteins in cancers, presumably due to large coding region sizes and the significant stochastic component to human mutagenesis. This cytoskeletal genomics result is consistent with the loss of cytoskeleton integrity as a hallmark of tumor development, but raises the question of whether such mutational sensitivity relates to the migration and invadopodia aspects of tumor progression. In the present study, the authors report that it is possible to identify a set of cytoskeletal related proteins protected from mutation, in comparison to the commonly mutated cytoskeleton related proteins in certain, but not all cancer, datasets.

Entities:  

Keywords:  The Cancer Genome Atlas; bladder cancer; cytoskeletal and extra-cellular matrix proteins; melanoma; metastasis; mutations

Year:  2017        PMID: 28804630      PMCID: PMC5526129          DOI: 10.3892/br.2017.940

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  23 in total

1.  Isolation and characterization of revertant cell lines. 3. Isolation of density-revertants of SV40-transformed 3T3 cells using colchicine.

Authors:  A Vogel; R Risser; R Pollack
Journal:  J Cell Physiol       Date:  1973-10       Impact factor: 6.384

2.  Defective organization of actin in cultured skin fibroblasts from patients with inherited adenocarcinoma.

Authors:  L Kopelovich; S Conlon; R Pollack
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

3.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

Review 4.  Directed migration of mesenchymal cells: where signaling and the cytoskeleton meet.

Authors:  James E Bear; Jason M Haugh
Journal:  Curr Opin Cell Biol       Date:  2014-07-05       Impact factor: 8.382

5.  Cytoskeletal F-actin patterns quantitated with fluorescein isothiocyanate-phalloidin in normal and transformed cells.

Authors:  M Verderame; D Alcorta; M Egnor; K Smith; R Pollack
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

6.  Flat cells come full sphere: Are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens?

Authors:  Michele L Parry; George Blanck
Journal:  Hum Vaccin Immunother       Date:  2015-07-30       Impact factor: 3.452

7.  Actin filament organization of the Dunning R3327 rat prostatic adenocarcinoma system: correlation with metastatic potential.

Authors:  J M Zachary; G Cleveland; L Kwock; T Lawrence; R M Weissman; L Nabell; F A Fried; E V Staab; M A Risinger; S Lin
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

8.  A Novel Approach to Evaluating Cancer Driver Gene Mutation Densities: Cytoskeleton-related Gene Candidates.

Authors:  Timothy J Fawcett; Michele L Parry; George Blanck
Journal:  Cancer Genomics Proteomics       Date:  2015 Nov-Dec       Impact factor: 4.069

9.  Dystrophin is a tumor suppressor in human cancers with myogenic programs.

Authors:  Yuexiang Wang; Adrian Marino-Enriquez; Richard R Bennett; Meijun Zhu; Yiping Shen; Grant Eilers; Jen-Chieh Lee; Joern Henze; Benjamin S Fletcher; Zhizhan Gu; Edward A Fox; Cristina R Antonescu; Christopher D M Fletcher; Xiangqian Guo; Chandrajit P Raut; George D Demetri; Matt van de Rijn; Tamas Ordog; Louis M Kunkel; Jonathan A Fletcher
Journal:  Nat Genet       Date:  2014-05-04       Impact factor: 38.330

10.  Non-metastatic 2 (NME2)-mediated suppression of lung cancer metastasis involves transcriptional regulation of key cell adhesion factor vinculin.

Authors:  Ram Krishna Thakur; Vinod Kumar Yadav; Akinchan Kumar; Ankita Singh; Krishnendu Pal; Luke Hoeppner; Dhurjhoti Saha; Gunjan Purohit; Richa Basundra; Anirban Kar; Rashi Halder; Pankaj Kumar; Aradhita Baral; M J Mahesh Kumar; Alfonso Baldi; Bruno Vincenzi; Laura Lorenzon; Rajkumar Banerjee; Praveen Kumar; Viji Shridhar; Debabrata Mukhopadhyay; Shantanu Chowdhury
Journal:  Nucleic Acids Res       Date:  2014-09-23       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.